Roche Under Fire Over ‘Unaffordable’ COVID-19 Therapy Actemra
World Health Organization Wants Prices Lowered
The World Health Organization has taken the unusual step of calling for lower drug prices to help COVID-19 patients access IL-6 therapies in developing nations.
You may also be interested in...
The availability later this month of Hetero's biosimilar tocilizumab, ostensibly a less pricey product, could place India in a relatively better situation to cope with any demand spurt should another wave of COVID-19 strike. Innovator product Actemra is expected to be in short supply, going by current trends, given the unprecedented worldwide demand.
Coronavirus Notebook: WHO Backs Actemra & Kevzara In COVID-19, German Body Says Remdesivir Has ‘Considerable Added Benefit’
The UK REACT-1 study has shown a threefold reduction in COVID-19 infections in double-vaccinated adults.
The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete own studies.